{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:39:51Z","timestamp":1776919191258,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40256-024-00710-z","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T18:37:28Z","timestamp":1734374248000},"page":"361-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy: A Meta-analysis of Randomized Placebo-Controlled Trials"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-3866","authenticated-orcid":false,"given":"Nicole","family":"Felix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7714-7148","authenticated-orcid":false,"given":"Larissa","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-6179","authenticated-orcid":false,"given":"Alleh","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-7786","authenticated-orcid":false,"given":"Amanda","family":"Godoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1789-6694","authenticated-orcid":false,"given":"Thomaz","family":"Alexandre Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-5685","authenticated-orcid":false,"given":"Jacqueline","family":"Pirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6990-4521","authenticated-orcid":false,"given":"Riyad Yazan","family":"Kherallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2103-2981","authenticated-orcid":false,"given":"Frans","family":"Serpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5644-9112","authenticated-orcid":false,"given":"Felipe Kalil Beir\u00e3o","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-8300","authenticated-orcid":false,"given":"Maria do Carmo","family":"Andrade Duarte de Farias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Vianna Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"710_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/ejhf.1715","volume":"22","author":"CV Tuohy","year":"2020","unstructured":"Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 2020;22:228\u201340. https:\/\/doi.org\/10.1002\/ejhf.1715.","journal-title":"Eur J Heart Fail"},{"key":"710_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001123","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Fugar S, Generoso G, Heard DG, Hiremath S, Ho JE, Kalani R, Kazi DS, Ko D, Levine DA, Liu J, Ma J, Magnani JW, Michos ED, Mussolino ME, Navaneethan SD, Parikh NI, Poudel R, Rezk-Hanna M, Roth GA, Shah NS, St-Onge M-P, Thacker EL, Virani SS, Voeks JH, Wang N-Y, Wong ND, Wong SS, Yaffe K, Martin SS, on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association. Circulation. 2023. https:\/\/doi.org\/10.1161\/CIR.0000000000001123.","journal-title":"Circulation"},{"key":"710_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa021332.","journal-title":"N Engl J Med"},{"key":"710_CR4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I, For the SHaRe Investigators. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation. 2018;138:1387\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.033200.","journal-title":"Circulation"},{"issue":"2011","key":"710_CR5","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"58","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011;58(2011):e212\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2011.06.011.","journal-title":"J Am Coll Cardiol"},{"issue":"2020","key":"710_CR6","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;76(2020):e159\u2013240. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.045.","journal-title":"J Am Coll Cardiol"},{"key":"710_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D, Bartunek J, Bondue A, Van Craenenbroeck E, Kubanek M, Zemanek D, Jensen M, Mogensen J, Thune JJ, Charron P, Hagege A, Lairez O, Trochu J-N, Axthelm C, Duengen H-D, Frey N, Mitrovic V, Preusch M, Schulz-Menger J, Seidler T, Arad M, Halabi M, Katz A, Monakier D, Paz O, Viskin S, Zwas D, Olivotto I, Brunner-La Rocca HP, Michels M, Dudek D, Oko-Sarnowska Z, Oreziak A, Wojakowski W, Cardim N, Pereira H, Barriales-Villa R, Garc\u00eda Pavia P, Gimeno Blanes J, Hidalgo Urbano R, Rinc\u00f3n Diaz LM, Elliott P, Yousef Z, Abraham T, Afshar K, Alvarez P, Bach R, Becker R, Choudhury L, Fermin D, Jacoby D, Jefferies J, Kramer C, Lakdawala N, Lester S, Marian A, Masri A, Maurer M, Nagueh S, Owens A, Owens D, Rader F, Saberi S, Sherrid M, Shirani J, Symanski J, Turer A, Wang A, Wever-Pinzon O, Wheeler M, Wong T, Yamani M. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X.","journal-title":"Lancet"},{"key":"710_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81:34\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.020.","journal-title":"J Am Coll Cardiol"},{"key":"710_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.10.059","author":"M Yassen","year":"2023","unstructured":"Yassen M, Changal K, Busken J, Royfman R, Schodowski E, Venkataramany B, Khouri SJ, Moukarbel GV. The efficacy of cardiac myosin inhibitors versus placebo in patients with symptomatic hypertrophic cardiomyopathy\u2014a meta-analysis and systematic review. Am J Cardiol. 2023. https:\/\/doi.org\/10.1016\/j.amjcard.2023.10.059.","journal-title":"Am J Cardiol"},{"key":"710_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2023.05.019","author":"D Bishev","year":"2023","unstructured":"Bishev D, Fabara S, Loseke I, Alok A, Al-Ani H, Bazikian Y. Efficacy and safety of mavacamten in the treatment of hypertrophic cardiomyopathy: a systematic review. Heart Lung Circul. 2023. https:\/\/doi.org\/10.1016\/j.hlc.2023.05.019.","journal-title":"Heart Lung Circul"},{"key":"710_CR11","doi-asserted-by":"publisher","first-page":"FSO898","DOI":"10.2144\/fsoa-2023-0059","volume":"9","author":"A Memon","year":"2023","unstructured":"Memon A, Larik MO, Khan Z, Urooj M, Irfan A, Kumari B, Faisal M, Siddiqui R, Tehrim M, Hameed I. Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis. Future Sci OA. 2023;9:FSO898. https:\/\/doi.org\/10.2144\/fsoa-2023-0059.","journal-title":"Future Sci OA"},{"key":"710_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101429","volume":"48","author":"M Ismayl","year":"2023","unstructured":"Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Mavacamten treatment for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2023;48: 101429. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101429.","journal-title":"Curr Probl Cardiol"},{"key":"710_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s43044-023-00328-7","volume":"75","author":"M Rabiee Rad","year":"2023","unstructured":"Rabiee Rad M, Ghasempour Dabaghi G, Habibi D. Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials. Egypt Heart J. 2023;75:4. https:\/\/doi.org\/10.1186\/s43044-023-00328-7.","journal-title":"Egypt Heart J"},{"key":"710_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D, The PRISMA. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"710_CR15","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane Collaboration; 2022. www.training.cochrane.org\/handbook."},{"key":"710_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/9781119099369","volume-title":"Systematic reviews in health research: meta-analysis in context","author":"M Egger","year":"2022","unstructured":"Egger M, Higgins JPT, Smith GD. Systematic reviews in health research: meta-analysis in context. 3rd ed. Hoboken: Wiley; 2022.","edition":"3"},{"key":"710_CR17","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27:1785\u2013805. https:\/\/doi.org\/10.1177\/0962280216669183.","journal-title":"Stat Methods Med Res"},{"key":"710_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"710_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, Cremer PC, Schaff H, McErlean E, Sewell C, Li W, Sterling L, Lampl K, Edelberg JM, Sehnert AJ, Nissen SE. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80:95\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.048.","journal-title":"J Am Coll Cardiol"},{"key":"710_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3030","author":"Z Tian","year":"2023","unstructured":"Tian Z, Li L, Li X, Wang J, Zhang Q, Li Z, Peng D, Yang P, Ma W, Wang F, Jin W, Cheng X, Sun J, Fu Y, Lyu C, Zhang S. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol. 2023. https:\/\/doi.org\/10.1001\/jamacardio.2023.3030.","journal-title":"JAMA Cardiol"},{"key":"710_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCGENETICS.111.960831","volume":"5","author":"SP Page","year":"2012","unstructured":"Page SP, Kounas S, Syrris P, Christiansen M, Frank-Hansen R, Andersen PS, Elliott PM, McKenna WJ. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Circ Cardiovasc Genet. 2012;5:156\u201366. https:\/\/doi.org\/10.1161\/CIRCGENETICS.111.960831.","journal-title":"Circ Cardiovasc Genet"},{"key":"710_CR22","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","volume":"49","author":"MP Grillo","year":"2019","unstructured":"Grillo MP, Erve JCL, Dick R, Driscoll JP, Haste N, Markova S, Brun P, Carlson TJ, Evanchik M. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica. 2019;49:718\u201333. https:\/\/doi.org\/10.1080\/00498254.2018.1495856.","journal-title":"Xenobiotica"},{"key":"710_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4250\/jcvi.2022.0053","volume":"31","author":"K Kim","year":"2023","unstructured":"Kim K, Lee SD, Lee HJ, Kim H, Kim HR, Cho YH, Jang JY, Kang MG, Koh J-S, Hwang S-J, Hwang J-Y, Park JR. Role and clinical importance of progressive changes in echocardiographic parameters in predicting outcomes in patients with hypertrophic cardiomyopathy. J Cardiovasc Imaging. 2023;31:85. https:\/\/doi.org\/10.4250\/jcvi.2022.0053.","journal-title":"J Cardiovasc Imaging"},{"key":"710_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.08.061","author":"CF Sherrod","year":"2024","unstructured":"Sherrod CF, Spertus JA, Gosch KL, Wang A, Elliott PM, Lakdawala NK, Reaney M, Zhong Y, Lam J, Wyrwich KW, Sauer AJ. The Kansas City Cardiomyopathy Questionnaire in relation to New York Heart Association Class. J Cardiac Fail. 2024. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.061.","journal-title":"J Cardiac Fail"},{"key":"710_CR25","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.jacc.2024.08.014","volume":"84","author":"CF Sherrod","year":"2024","unstructured":"Sherrod CF, Saberi S, Nassif ME, Claggett BL, Coats CJ, Garcia-Pavia P, Januzzi JL, Lewis GD, Ma C, Maron MS, Miao ZM, Olivotto I, Veselka J, Butzner M, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Spertus JA. Effect of aficamten on health status outcomes in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2024;84:1773\u201385. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.014.","journal-title":"J Am Coll Cardiol"},{"key":"710_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcae092","author":"SAC Schoonvelde","year":"2024","unstructured":"Schoonvelde SAC, Wiethoff I, Zwetsloot PP, Hirsch A, Knackstedt C, Germans T, Sikking M, Schinkel AFL, Van Slegtenhorst MA, Verhagen JMA, De Boer RA, Evers SMAA, Hiligsmann M, Michels M. Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study. Eur Heart J Qual Care Clin Outcomes. 2024. https:\/\/doi.org\/10.1093\/ehjqcco\/qcae092.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"710_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2023.08.006","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wang A. Medical therapies for hypertrophic cardiomyopathy: current state of the art. Progr Cardiovasc Dis. 2023. https:\/\/doi.org\/10.1016\/j.pcad.2023.08.006.","journal-title":"Progr Cardiovasc Dis"},{"key":"710_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jacc.2022.10.027","volume":"81","author":"A Mentias","year":"2023","unstructured":"Mentias A, Smedira NG, Krishnaswamy A, Reed GW, Ospina S, Thamilarasan M, Popovic ZB, Xu B, Kapadia SR, Desai MY. Survival after septal reduction in patients >65 years old with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81:105\u201315. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.027.","journal-title":"J Am Coll Cardiol"},{"key":"710_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79:390\u2013414. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.021.","journal-title":"J Am Coll Cardiol"},{"key":"710_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/HCO.0000000000001068","volume":"38","author":"S Chatur","year":"2023","unstructured":"Chatur S, Hegde SM. Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy. Curr Opin Cardiol. 2023;38:424\u201332. https:\/\/doi.org\/10.1097\/HCO.0000000000001068.","journal-title":"Curr Opin Cardiol"},{"key":"710_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3342","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Smedira NG, Schaff H, McErlean E, Sewell C, Mudarris L, Gong Z, Lampl K, Sehnert AJ, Nissen SE. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 2023. https:\/\/doi.org\/10.1001\/jamacardio.2023.3342.","journal-title":"JAMA Cardiol"},{"key":"710_CR32","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, De Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP, ESC Scientific Document Group, Charron P, Imazio M, Abdelhamid M, Aboyans V, Arad M, Asselbergs FW, Asteggiano R, Bilinska Z, Bonnet D, Bundgaard H, Cardim NM, \u010celutkien\u0117 J, Cikes M, De Ferrari GM, Dusi V, Falk V, Fauchier L, Gandjbakhch E, Heli\u00f6 T, Koskinas K, Kotecha D, Landmesser U, Lazaros G, Lewis BS, Linhart A, L\u00f8chen M-L, Meder B, Mindham R, Moon J, Nielsen JC, Petersen S, Prescott E, Sheppard MN, Sinagra G, Sitges M, Tfelt-Hansen J, Touyz R, Veltrop R, Veselka J, Wahbi K, Wilde A, Zeppenfeld K, Kichou B, Sisakian H, Scherr D, Gerber B, D\u017eubur A, Gospodinova M, Planinc I, Moustra HH, Zem\u00e1nek D, Jensen MSK, Samir A, Palm K, Heli\u00f6 T, Wahbi K, Schulze-Bahr E, Haralambos V, Sepp R, A\u00f0alsteinsd\u00f3ttir B, Ward D, Blich M, Sinagra G, Poniku A, Lunegova O, Rudzitis A, Kassab R, Barysien\u0117 J, Huijnen S, Felice T, Vataman E, Pavlovic N, Doghmi N, Asselbergs FW, Kostovska ES, Almaas VM, Biernacka EK, Brito D, Rosca M, Zavatta M, Ristic A, Goncalvesov\u00e1 E, \u0160inkovec M, Ca\u00f1adas-Godoy V, Platonov PG, Saguner AM, Saadi ARA, Kammoun I, Celik A, Nesukay E, Abdullaev T, Prescott E, James S, Arbelo E, Baigent C, Borger MA, Buccheri S, Ibanez B, K\u00f8ber L, Koskinas KC, McEvoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Pasquet A, Rakisheva A, Rocca B, Rossello X, Vaartjes I, Vrints C, Witkowski A, Zeppenfeld K. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503\u2013626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194.","journal-title":"Eur Heart J"},{"key":"710_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001250","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024. https:\/\/doi.org\/10.1161\/CIR.0000000000001250.","journal-title":"Circulation"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00710-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00710-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00710-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:14:42Z","timestamp":1745324082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00710-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["710"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00710-z","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"27 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for conducting this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"G.V.S. reports contracts as a lecturer and proctor for Abbott and Medtronic. Remaining authors report no conflicts of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This meta-analysis did not require informed consent or institutional review board approval, for all data are publicly available and did not involve access to individual patient data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Data will be fully available upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"N.F. carried out study conceptualization and project administration; N.F., L.T., and A.N. carried out the methodology and investigation; N.F. and A.N. carried out data curation, software, formal analysis, and visualization; N.F., L.T., A.N., A.G., T.A.G., and J.P. carried out writing\u2014original draft preparation; N.F., L.T., R.Y.K., F.S., F.C.B.A., M.d.C.A.D.d.F., and G.V.S. carried out writing\u2014review and editing; M.d.C.A.D.d.F. and G.V.S. carried out supervision.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}